In a snapshot of its rare disease data, Ultragenyx boosts case for new surrogate biomarker

Ul­tragenyx took a step to­ward es­tab­lish­ing a po­ten­tial new sur­ro­gate bio­mark­er Tues­day morn­ing, pre­sent­ing da­ta for a rare dis­ease with no ap­proved treat­ments.

Re­searchers are study­ing whether an AAV gene ther­a­py can treat San­fil­ip­po syn­drome type A (MPS II­IA) by re­duc­ing the buildup of cer­tain car­bo­hy­drates in the brain and cere­brospinal flu­id. The dis­ease stems from a ge­net­ic de­fect caus­ing the body to be un­able to break down and re­cy­cle the car­bo­hy­drate, lead­ing to neu­rode­vel­op­men­tal and phys­i­cal de­cline ear­ly in child­hood and even­tu­al­ly death, usu­al­ly be­fore in­di­vid­u­als turn 20.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.